SXTC 6-K
China SXT Pharmaceuticals, Inc. (SXTC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March
Commission File Number:
(Translation of registrant’s name into English)
178 Taidong Rd North, Taizhou
Jiangsu, China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Explanatory Note
China SXT Pharmaceuticals, Inc. (the “Company”) is furnishing this Form 6-K to provide its financial results for the six months ended September 30, 2024.
The Company hereby furnishes the following documents as the exhibits to this report: “Unaudited Condensed Consolidated Financial Statements for the six months ended September 30, 2024 and 2023” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.
1
Exhibits
| Exhibit No. | Description | |
| 99.1 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | |
| 99.2 | Unaudited Condensed Consolidated Financial Statements for the six months ended September 30, 2024 and 2023 | |
| 101.INS | Inline XBRL Instance Document. | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: March 28, 2025
| China SXT Pharmaceuticals, Inc. | ||
| By: | /s/ Feng Zhou | |
| Name: | Feng Zhou | |
| Title: | Co-Chief Executive Officer | |
| By: | /s/ Simon Lim Sze Beng | |
| Name: | Simon Lim Sze Beng | |
| Title: | Co-Chief Executive Officer |
3